Sustained correction of disease in naive and AAV2-pretreated hemophilia B dogs: AAV2/8-mediated, liver-directed gene therapy
The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Abstract
Adeno-associated virus 8 (AAV8), a new member of the AAV family isolated from nonhuman primates, is an attractive candidate for hepatic gene transfer applications because of 10- to 100-fold improved transduction efficiency in mouse liver models. Additionally, AAV8 has lesser frequency of pre-existing immunity in humans. These properties could solve some of the problems associated with AAV2 vectors. The benefits of AAV8 demonstrated in mouse models, however, have not been confirmed in larger animals. In this study, we evaluate the efficacy and safety of AAV2/8 vector in both naive and AAV2-pretreated hemophilia B dogs. Two naive hemophilia B dogs that received a single intraportal administration of AAV2/8 vector have achieved sustained expression of 10% and 26% of normal levels of canine factor IX (cFIX) for more than a year. In an AAV2-pretreated hemophilia B dog, cFIX expression increased from less than 1% to 16% of normal levels when treated with an AAV2/8 vector, and a high level of expression has lasted for more than 2 years. No significant liver toxicity or cFIX-specific antibodies have been detected in these animals. Studies here have demonstrated the safety and improved efficacy of AAV2/8 vector in large-animal models for liver-directed gene therapy.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Also, no signi fi cant liver toxicity and antibody formation was observed in this study.”
From A versatile toolkit for overcoming AAV immunity (2022) · cites this paper as [184]
In the citing paper
“In a canine model of hemophilia B, a second administration of AAV8 in AAV2pretreated dog increased FIX level from <1% to 16% of normal controls and lasted for 2 years (184).”
From A versatile toolkit for overcoming AAV immunity (2022) · cites this paper as [184]
In the citing paper
“Therefore, using alternative capsid variant with low immunogenicity was shown to be a viable option for achieving ef fi cient transduction in animal studies (178 -184).”
From A versatile toolkit for overcoming AAV immunity (2022) · cites this paper as [184]
Citations
Cites
Guide for the Care and Use of Laboratory Animals: Eighth Edition
(2011) · doi:10.17226/12910 · Cited by 16,199
Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy
Gao, G.-P., Alvira, M. R., Wang, L., Calcedo, R., Johnston, J., & Wilson, J. M. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.182412299 · Cited by 1,520 · cited 7×
“AAV neutralizing antibody assays AAV2, 2/5, and 2/8 neutralizing antibody titers in canine serums were assayed by the ability of serums to inhibit transduction of 84-31 cells by reporter viruses (AAVCMVEGFP) of the respective serotypes as described.(19) Specifically, the reporter virus AAVCMVEGFP of each serotype (at…”
BackgroundMethodInfluentialSelf-citationXiao, X., Li, J., & Samulski, R. J. (1998) · Journal of Virology · doi:10.1128/jvi.72.3.2224-2232.1998 · Cited by 1,381 · cited 1×
“AAV vectors were produced by three plasmids cotransfection methods as described by Xiao et al.(21) with modifications.”
MethodClades of Adeno-Associated Viruses Are Widely Disseminated in Human Tissues
Gao, G., Vandenberghe, L. H., Alvira, M. R., Lu, Y., Calcedo, R., Zhou, X., & Wilson, J. M. (2004) · Journal of Virology · doi:10.1128/jvi.78.12.6381-6388.2004 · Cited by 1,070 · cited 1×
“We have recently identified an expanding family of AAVs from human and nonhuman primate tissues of which at least 3 are serologically different from serotypes 1-6; these are called AAV7, 8, 9.(13) Pseudotyping strategies have been developed to cross package vector with AAV2 ITRs with capsids from other serotypes.”
BackgroundSelf-citationCurrent Protocols in Human Genetics
(2001) · John Wiley & Sons, Inc. eBooks · doi:10.1002/0471142905 · Cited by 987
Rabinowitz, J. E., Rolling, F., Li, C., Conrath, H., Xiao, W., Xiao, X., & Samulski, R. J. (2002) · Journal of Virology · doi:10.1128/jvi.76.2.791-801.2002 · Cited by 762 · cited 1×
“Pseudotyping strategies have been developed to cross package vector with AAV2 ITRs with capsids from other serotypes.(14) Increased in vivo gene transfer efficiency with vectors of other AAV serotypes have been reported.”
BackgroundSnyder, R. O., Miao, C. H., Patijn, G. A., Spratt, S. K., Danos, O., Nagy, D., Gown, A. M., Winther, B., Meuse, L., Cohen, L. K., et al. (1997) · Nature Genetics · doi:10.1038/ng0797-270 · Cited by 579
Gene therapy vectors based on adeno-associated virus type 1
Xiao, W., Chirmule, N., Berta, S. C., McCullough, B., Gao, G., & Wilson, J. M. (1999) · Journal of Virology · doi:10.1128/jvi.73.5.3994-4003.1999 · Cited by 541
Self-citationNakai, H., Yant, S. R., Storm, T. A., Fuess, S., Meuse, L., & Kay, M. A. (2001) · Journal of Virology · doi:10.1128/jvi.75.15.6969-6976.2001 · Cited by 478
Induction of Immune Tolerance to Coagulation Factor IX Antigen by In Vivo Hepatic Gene Transfer
Mingozzi, F., Liu, Y.-L., Dobrzynski, E., Kaufhold, A., Liu, J. H., Wang, Y., Arruda, V. R., High, K. A., & Herzog, R. W. (2003) · Journal of Clinical Investigation · doi:10.1172/jci16887 · Cited by 466 · cited 1×
“10 Inhibitor formation against FIX by this route of administration in mice is very rare, although it could happen in some strains of mice and it correlated with low FIX expression.(11) Among the hemophilia B dogs treated with AAV vectors via the liver approach, only one dog with the null mutation developed anti-cFIX a…”
Background
Cited by
Manno, C. S., Pierce, G. F., Arruda, V. R., Glader, B., Ragni, M., Rasko, J. J. E., Ozelo, M. C., Hoots, K., Blatt, P., Konkle, B., et al. (2006) · Nature Medicine · doi:10.1038/nm1358 · Cited by 2,163
Therapeutic in vivo gene transfer for genetic disease using AAV: Progress and challenges
Mingozzi, F., & High, K. A. (2011) · Nature Reviews Genetics · doi:10.1038/nrg2988 · Cited by 893
Emerging issues in AAV-mediated in vivo gene therapy
Colella, P., Ronzitti, G., & Mingozzi, F. (2018) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2017.11.007 · Cited by 881
Grimm, D., Lee, J. S., Wang, L., Desai, T., Akache, B., Storm, T. A., & Kay, M. A. (2008) · Journal of Virology · doi:10.1128/jvi.00254-08 · Cited by 696
Self-citationThe AAV Vector Toolkit: Poised at the Clinical Crossroads
Asokan, A., Schaffer, D. V., & Jude Samulski, R. (2012) · Molecular Therapy · doi:10.1038/mt.2011.287 · Cited by 465
Metadata
- Authors
- Wang, L., Calcedo, R., Nichols, T. C., Bellinger, D. A., Dillow, A., Verma, I. M., & Wilson, J. M.
- Affiliations
- University of North Carolina at Chapel Hill (US)
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2005-04-15
- Volume
- 105
- Issue
- 8
- Pages
- 3079-3086
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W2000185853
- Cited by
- 173
- References
- 35
- Citations by year
- 2026: 2 · 2025: 3 · 2024: 4 · 2023: 1 · 2022: 2 · 2021: 2 · 2020: 1 · 2019: 5 · 2018: 5 · 2017: 5 · 2016: 6 · 2015: 5 · 2014: 8 · 2013: 11 · 2012: 10
- FWCI
- 11.37
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Blood (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Heart, Lung, and Blood Institute (2-P01-HL-059407-06A1, HL53670, P01HL064190, P01HL059407, R24HL063098, HL-63 098, R01HL053670)
- National Institute of Diabetes and Digestive and Kidney Diseases (P30DK047757, 5-P30-DK-47757-12)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Health Sciences › Medicine › Hematology › Hemophilia Treatment and Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Keywords
- hemophilia B, adeno-associated virus 8, liver-directed gene therapy, large animal model, sustained gene expression, vector safety
- MeSH terms
- Dependovirus, Animals, Antibodies, Hemophilia B, Disease Models, Animal, Dogs, Factor IX, Genetic Vectors, Hemorrhage, Liver, Portal System, Genetic Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Sustained correction of disease in naive and AAV2-pretreated hemophilia B dogs: AAV2/8-mediated, liver-directed gene therapy. https://app.cochat.ai/papers/10.1182/blood-2004-10-3867
- The paper
- Wang, L., Calcedo, R., Nichols, T. C., Bellinger, D. A., Dillow, A., Verma, I. M., & Wilson, J. M. (2005). Sustained correction of disease in naive and AAV2-pretreated hemophilia B dogs: AAV2/8-mediated, liver-directed gene therapy. Blood. https://doi.org/10.1182/blood-2004-10-3867
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.